C-reactive protein in patients with COVID-19: A scoping review

Fares M Muthanna; Hamza Khalifa Ibrahim; Noor-Alhooda Milood Al-Awkally; Aejeeliyah Yousuf; Kamilia Mounich

doi:10.53730/ijhs.v6nS5.8920

Authors

Fares M Muthanna
fariszaydi@gmail.com
Department of Pharmaceutical Care, School of Pharmacy, Walailak University, Nakhon Si Thammarat, 80160, Thailand
Hamza Khalifa Ibrahim Department of pharmacy, Higher Institute of medical Technology, Bani Waleed, Libya
Noor-Alhooda Milood Al-Awkally Medical laboratory Department, High Institute of Science and Technology, Suluq, Libya
Aejeeliyah Yousuf Medical laboratory Department, Higher Institute of medical Technology, Bani Waleed, Libya
Kamilia Mounich Hassan II University of Casablanca, LEPE, Higher School of Technology, Casablanca, Morocco

Keywords:

C-reactive protein, CRP, COVID-19, SARS virus

Abstract

The coronavirus illness 2019 (COVID-19) has spread to over 200 countries and infected over 70 million individuals since December 2019. The precise nature of the SARS-CoV-2 infection is yet unknown. In this study, we look at whether a C-reactive protein biomarker can predict clinical outcome or is linked to the severity of COVID-19 illness. Potential research published from the COVID-19 pandemic to May 2022 was found using the databases MEDLINE, Hinari, Google Scholar, and Google search. To extract relevant facts from each original report, a format established in a Microsoft Excel spreadsheet was employed. The retrieved data were transferred to STATA/MP version 16.0 software for further analysis. Keywords such as "COVID-19," "SARS-CoV-2," and "C-reactive protein," among others, were searched to find relevant papers. Only studies that reported mean C-reactive protein levels and COVID-19 disease stage results were included. The review contained twenty papers. All investigations indicated that individuals with severe COVID-19 had considerably greater levels of C-reactive protein than patients with moderate illness. This review indicated that a specific biomarker may still be used to predict the risk of disease progression in asymptomatic and/or slightly too seriously unwell persons.

Downloads

Download data is not yet available.

References

World Health Organization. Pneumonia of unknown cause— China [Internet]. WHO; 2020 [cited 2021, May 9]. Available from: https://www.who.int/csr/don/05-january-2020-peumonia-ofunkown- cause-china/en/

Lippi G, Sanchis-Gomar F, Henry BM. Coronavirus disease 2019 (COVID-19): the portrait of a perfect storm. Ann Transl Med. 2020;8:497. https://doi.org/10.21037/atm.2020.03.157

Schulman S. Coronavirus disease 2019, prothrombotic factors, and venous thromboembolism. Semin Thromb Hemost. 2020; 46:772-776. https://doi.org/10.1055/s-0040-1710337

Kwaan HC. Coronavirus disease 2019: The role of the fibrinolytic system from transmission to organ injury and sequelae. Semin Thromb

Luan YY and Yao YM. The clinical significance and potential role of C-reactive protein in chronic inflammatory and neurodegenerative diseases. Front Immunol 2018; 9: 1302–1308.

Chen, W., Zheng, K. I., Liu, S., Yan, Z., Xu, C., & Qiao, Z. (2020). Plasma CRP level is positively associated with the severity of COVID-19. Annals of clinical microbiology and antimicrobials, 19(1), 1-7.

Ali, N. (2020). Elevated level of C‐reactive protein may be an early marker to predict risk for severity of COVID‐19. Journal of medical virology.

Wang, L. (2020). C-reactive protein levels in the early stage of COVID-19. Medecine et maladies infectieuses, 50(4), 332-334.

Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta. 2020;506:145-148. https://doi. org/10.1016/j.cca.2020.03.022

Chen W, Zheng KI, Liu S, Yan Z, Xu C, Qiao Z. Plasma CRP level is positively associated with the severity of COVID-19. Ann Clin Microbiol Antimicrob. 2020;19:18. https://doi.org/10.1186/s12941- 020-00362-2

Sproston NR, Ashworth JJ. Role of C-Reactive protein at sites of inflammation and infection. Front Immunol. 2018;9:754. https:// doi.org/10.3389/fimmu.2018.00754

Du Clos TW. Function of C-reactive protein. Ann Med. 2000; 32:274-278. https://doi.org/10.3109/07853890009011772

Bhardwaj N, Ahmed MZ, Sharma S, Nayak A, Anvikar AR, Pande V. C-reactive protein as a prognostic marker of Plasmodium falciparum malaria severity. J Vector Borne Dis. 2019;56:122-126. https://doi.org/10.4103/0972-9062.263727

de Souza Pires-Neto O, da Silva Graça Amoras E, Queiroz MAF, Demachki S, da Silva Conde SR, Ishak R, et al. Hepatic TLR4, MBL and CRP gene expression levels are associated with chronic hepatitis C. Infect Genet Evol. 2020;80:104200. https://doi.org/10. 10

Sadeghi-Haddad-Zavareh, M., Bayani, M., Shokri, M., Ebrahimpour, S., Babazadeh, A., Mehraeen, R., ... & Javanian, M. (2021). C-reactive protein as a prognostic indicator in COVID-19 patients. Interdisciplinary Perspectives on Infectious Diseases, 2021.

Velavan, T. P., & Meyer, C. G. (2020). Mild versus severe COVID-19: laboratory markers. International Journal of Infectious Diseases, 95, 304-307.

Han, J., Shi, L. X., Xie, Y., Zhang, Y. J., Huang, S. P., Li, J. G., ... & Shao, S. F. (2020). Analysis of factors affecting the prognosis of COVID-19 patients and viral shedding duration. Epidemiology & Infection, 148.

Acar, E., Demir, A., Yıldırım, B., Kaya, M. G., & Gökçek, K. (2021). The role of hemogram parameters and C‐reactive protein in predicting mortality in COVID‐19 infection. International journal of clinical practice, 75(7), e14256.

Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol. 2021;93:250-256. https://doi.org/10.1002/jmv.26232

Li X, Marmar T, Xu Q, Tu J, Yin Y, Tao Q, et al. Predictive indicators of severe COVID-19 independent of comorbidities and advanced age: a nested case-control study. Epidemiol Infect. 2020;148:e255. https://doi.org10.1017/S0950268820002502

Mueller AA, Tamura T, Crowley CP, DeGrado JR, Haider H, Jezmir JL, et al. Inflammatory biomarker trends predict respiratory decline in COVID-19 patients. Cell Rep Med. 2020;1:100144. https://doi.org10.1016/j.xcrm.2020.100144

Ahnach M, Zbiri S, Nejjari S, Ousti F, Elkettani C. C-reactive protein as an early predictor of COVID-19 severity. J Med Biochem. 2020;39:500-507. https://doi.org/10.5937/jomb0-27554

Sadeghi-Haddad-Zavareh M, Bayani M, Shokri M, Ebrahimpour S, Babazadeh A, Mehraeen R, et al. C-reactive protein as a prognostic indicator in COVID-19 patients. Interdiscip Perspect Infect Dis. 2021;2021:5557582. https://doi.org/10.1155/2021/5557582

Stringer D, Braude P, Myint PK, Evans L, Collins JT, Verduri A, et al. The role of C-reactive protein as a prognostic marker in COVID-19. Int J Epidemiol. 2021;50:420-429. https://doi.org/ 10.1093/ije/dyab012

Poggiali E, Zaino D, Immovilli P, Rovero L, Losi G, Dacrema A, et al. Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients. Clin Chim Acta. 2020; 509:135-138. https://doi.org/10.1016/j.cca.2020.06.012

Ahnach M, Zbiri S, Nejjari S, Ousti F, Elkettani C. C-reactive protein as an early predictor of COVID-19 severity. J Med Biochem. 2020;39:500-507. https://doi.org/10.5937/jomb0-27554

Shang W, Dong J, Ren Y, Tian M, Li W, Hu J, et al. The value of clinical parameters in predicting the severity of COVID-19. J Med Virol. 2020;92:2188-2192. https://doi.org/10.1002/jmv.26031

Xue G, Gan X, Wu Z, Xie D, Xiong Y, Hua L, et al. Novel serological biomarkers for inflammation in predicting disease severity in patients with COVID-19. Int Immunopharmacol. 2020; 89:107065. https://doi.org/10.1016/j.intimp.2020.107065

Aksel G, İslam MM, Algın A, Eroğlu SE, Yaşar GB, Ademoğlu E, et al. Early predictors of mortality for moderate to severely ill patients with Covid-19. Am J Emerg Med. 2021:45:290-296. https:// doi.org/10.1016/j.ajem.2020.08.076

Wang Z, Wang Z. Identification of risk factors for in-hospital death of COVID - 19 pneumonia –lessions from the early outbreak. BMC Infect Dis. 2021;21:113. https://doi.org/10.1186/s12879-021- 05814-4

Ullah W, Thalambedu N, Haq S, Saeed R, Khanal S, Tariq A, et al. Predictability of CRP and D-Dimer levels for in-hospital outcomes and mortality of COVID-19. J Community Hosp Intern Med Perspect. 2020;10:402-408. https://doi.org/10.1080/20009666. 2020.1798

Smilowitz NR, Kunichoff D, Garshick M, Shah B, Pillinger M, Hochman JS, et al. C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J. 2021;42:2270-2279. https://doi.org/10.1093/eurheartj/ehaa1103

Laguna-Goya R, Utrero-Rico A, Talayero P, Lasa-Lazaro M, Ramirez-Fernandez A, Naranjo L, et al. IL-6-based mortality risk model for hospitalized patients with COVID-19. J Allergy Clin Immunol. 2020;146:799-807.e9. https://doi.org/10.1016/j.jaci. 2020.07.00

Liu SL, Wang SY, Sun YF, Jia QY, Yang CL, Cai PJ, et al. Expressions of SAA, CRP, and FERR in different severities of COVID-19. Eur Rev Med Pharmacol Sci. 2020;24:11386-11394. https://doi.org/10.26355/eurrev_202011_23631

Liu YP, Li GM, He J, Liu Y, Li M, Zhang R, et al. Combined use of the neutrophil-to-lymphocyte ratio and CRP to predict 7-day disease severity in 84 hospitalized patients with COVID-19 pneumonia: a retrospective cohort study. Ann Transl Med. 2020;8:635. Ht

Yamada T, Wakabayashi M, Yamaji T, Chopra N, Mikami T, Miyashita H, et al. Value of leukocytosis and elevated C-reactive protein in predicting severe coronavirus 2019 (COVID-19): A systematic review and meta-analysis. Clin Chim Acta. 2020;509: 235-243. Htt

Tan C, Huang Y, Shi F, Tan K, Ma Q, Chen Y, et al. C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early. J Med Virol. 2020;92:856-862. https://doi.org/10.1002/jmv.25871.

Keddie S, Ziff O, Chou MKL, Taylor RL, Heslegrave A, Garr E, et al. Laboratory biomarkers associated with COVID-19 severity and management. Clin Immunol. 2020;221:108614. https://doi.org/ 10.1016/j.clim.2020.108614

Wang G, Wu C, Zhang Q, Wu F, Yu B, Lv J, et al. C-reactive protein level may predict the risk of COVID-19 aggravation. Open Forum Infect Dis. 2020;7:ofaa153. https://doi.org/10.1093/ofid/ ofaa153

Luo, X., Zhou, W., Yan, X., Guo, T., Wang, B., Xia, H., ... & Yang, W. (2020). Prognostic value of C-reactive protein in patients with coronavirus 2019. Clinical Infectious Diseases, 71(16), 2174-2179.

Potempa, L. A., Rajab, I. M., Hart, P. C., Bordon, J., & Fernandez-Botran, R. (2020). Insights into the use of C-reactive protein as a diagnostic index of disease severity in COVID-19 infections. The American journal of tropical medicine and hygiene, 103(2), 561.

Velavan, T. P., & Meyer, C. G. (2020). Mild versus severe COVID-19: laboratory markers. International Journal of Infectious Diseases, 95, 304-307.

Xu, X., Yu, M. Q., Shen, Q., Wang, L. Z., Yan, R. D., Zhang, M. Y., Liu, J. Y., & Qu, Y. Q. (2020). Analysis of inflammatory parameters and disease severity for 88 hospitalized COVID-19 patients in Wuhan, China. International journal of medical sciences, 1

Wang L. C-reactive protein in the early stages of COVID-19. Med Mal infect. 2020;50:332-334. https://doi.org/10.1016/j.medmal. 2020.03.007

Khaliha, Hamza, Abdulfatah Saed, and Samira Daw. "Hydroxychloroquine And Dexamethasone Are Both Possible For Treatment Of Covid-19."‏

Ibrahim, Hamza Khalifa, et al. "The Most Commonly Used Drugs in Combating the Emerging Corona Virus Disease (Covid-19)."

Ibrahim, H. K., Ahseen, N. A., Ahmed, T. I., Ahseen, N. A., Al-Awkally, N.-A. M., & Yousuf, A. (2022). Evaluation of dexamethasone effects in COVID-19 treatment. International Journal of Health Sciences, 6(S1), 546-554. https://doi.org/10.53730/ijhs.v6nS1.4799

Arif, S., Zia, T., Qayyum, Z., Mustafa, G., Ateeq, M., Farhad, S., ... & Muthanna, F. M. (2022). Prevalence and Risk Factors of Covid-19 Mortality and its Impact on Social Life of Pakistani Population. Pakistan Journal of Medical & Health Sciences, 16(03), 800-800

Arif, S., Zia, T., Mustafa, G., Qayyum, Z., Ateeq, M., Faiz, M. J., ... & Ullah, I. (2022). Knowledge, Attitude and Practices of Medical Students Regarding Covid-19, Pakistan. Pakistan Journal of Medical & Health Sciences, 16(03), 783-783.

Muthanna, F. M., & Samad, A. (2022). Covid-19 Pendemic (Incidence, Risk factors and Treatment). BULLET: Jurnal Multidisiplin Ilmu, 1(01), 46-48.